The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa

Oncology Reports

Volumn 18, Issue 4, 2007, Pages 927-932

  Tian, Xiaoyu ^a,b   Chen, Gang ^a   Xing, Hui ^a   Weng, Danhui ^a   Guo, Yunhong ^b   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

DNA PK; Drug sensitivity; shRNA; Transfection; Tumor cell

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; CISPLATIN; DNA BINDING PROTEIN; DNA DEPENDENT PROTEIN KINASE; ETOPOSIDE; KU ANTIGEN; MESSENGER RNA; SMALL INTERFERING RNA; TOPOTECAN;

ARTICLE; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE SILENCING; GENETICS; HELA CELL; HUMAN; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, NUCLEAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE SILENCING; HELA CELLS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TOPOTECAN;

EID: 38449118996     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.4.927     Document Type: Article

References (35)

1. Yumoto Y, Shirakawa H, Yoshida M, Suwa A, Watanabe F and Teraoka H: High mobility group proteins 1 and 2 can function as DNA-binding regulatory components for DNA-dependent protein kinase in vitro. J Biochem 124: 519-527, 1998. (Pubitemid 28456871)
2. Pawelczak KS, Andrews BJ and Turchi JJ: Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Res 33: 152-161, 2005. (Pubitemid 40276937)
3. Yang J, Yu Y, Hamrick HE and Duerksen-Hughes PJ: ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24: 1571-1580, 2003. (Pubitemid 37304662)
4. Carney JP, Maser RS, Olivares H, et al: The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93: 477-486, 1998. (Pubitemid 28232091)
5. Moshous D, Callebaut I, de Chasseval R, et al: Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105: 177-186, 2001. (Pubitemid 32429508)
6. Nick McElhinny SA, Snowden CM, McCarville J and Ramsden DA: Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol 20: 2996-3003, 2000. (Pubitemid 30215012)
7. Calsou P, Delteil C, Frit P, Drouet J and Salles B: Coordinated assembly of Ku and p460 subunits of the DNA-dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV recruitment. J Mol Biol 326: 93-103, 2003. (Pubitemid 36279360)
8. Ruiz MT, Nichols A, Price GB and Zannis-Hadjopoulos M: DNA-PKcs-OBA/Ku associate in the absence of DNA, as revealed by two-dimensional capillary gel electromobility shift assay. Electrophoresis 23: 2485-2489, 2002.
9. Matheos D, Ruiz MT, Price GB and Zannis-Hadjopoulos M: Ku antigen, an origin-specific binding protein that associates with replication proteins, is required for mammalian DNA replication. Biochim Biophys Acta 1578: 59-72, 2002. (Pubitemid 35223457)
10. Li B and Comai L: Requirements for the nucleolytic processing of DNA ends by the Werner syndrome protein-Ku70/80 complex. J Biol Chem 276: 9896-9902, 2001.
11. Karmakar P, Snowden CM, Ramsden DA and Bohr VA: Ku heterodimer binds to both ends of the Werner protein and functional interaction occurs at the Werner N-terminus. Nucleic Acids Res 30: 3583-3591, 2002. (Pubitemid 34919214)
12. Tang D, Xie Y, Zhao M, Stevenson MA and Calderwood SK: Repression of the HSP70B promoter by NFIL6, Ku70, and MAPK involves three complementary mechanisms. Biochem Biophys Res Commun 280: 280-285, 2001. (Pubitemid 32917508)
13. Chai W, Ford LP, Lenertz L, Wright WE and Shay JW: Human Ku70/80 associates physically with telomerase through interaction with hTERT. J Biol Chem 277: 47242-47247, 2002. (Pubitemid 36159235)
14. Yazlovitskaya EM and Persons DL: Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res 23: 2275-2279, 2003. (Pubitemid 36897091)
15. Noguchi T, Shibata T, Fumoto S, Uchida Y, Mueller W and Takeno S: DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol 9: 1017-1022, 2002. (Pubitemid 35424638)
16. Eriksson A, Lewensoh R, Larsson R and Nilsson A: DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res 22: 1787-1793, 2002. (Pubitemid 34839197)
17. Omori S, Takiguchi Y, Suda A, et al: Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair 1: 299-310, 2002. (Pubitemid 38340226)
18. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75, 1999.
19. Judson I and Kelland LR: New developments and approaches in the platinum arena. Drugs 59 (Suppl 4): 29-38, 2000.
20. Karpinich NO, Tafani M, Rothman RJ, Russo MA and Farber JL: The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277: 16547-16552, 2002. (Pubitemid 34967670)
21. Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS and Pommier Y: Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J 18: 1397-1406, 1999. (Pubitemid 29110323)
22. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990. (Pubitemid 20218552)
23. Beck WT, Morgan SE, Mo YY and Bhat UG: Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. Drug Resist Updat 2: 382-389, 1999. (Pubitemid 30159140)
24. el-Deiry WS: Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9: 79-87, 1997.
25. Larsen AK and Skladanowski A: Cellular resistance to topoisomerase- targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400: 257-274, 1998. (Pubitemid 28475108)
26. Pommier Y, Pourquier P, Urasaki Y, Wu J and Laco GS: Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2: 307-318, 1999. (Pubitemid 30070455)
27. Kruczynski A, Barret JM, Van Hille B, et al: Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clin Cancer Res 10: 3156-3168, 2004. (Pubitemid 38619697)
28. Belenkov AI, Paiement JP, Panasci LC, Monia BP and Chow TY: An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res 62: 5888-5896, 2002. (Pubitemid 35204750)
29. Deriano L, Guipaud O, Merle-Beral H, et al: Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105: 4776-4783, 2005. (Pubitemid 40807303)
30. Durant S and Karran P: Vanillins - a novel family of DNA-PK inhibitors. Nucleic Acids Res 31: 5501-5512, 2003. (Pubitemid 37441920)
31. Eriksson A, Yachnin J, Lewensohn R and Nilsson A: DNA-dependent protein kinase is inhibited by trifluoperazine. Biochem Biophys Res Commun 283: 726-731, 2001. (Pubitemid 32924638)
32. Ayene IS, Ford LP and Koch CJ: Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Mol Cancer Ther 4: 529-536, 2005. (Pubitemid 40601833)
33. Frit P, Canitrot Y, Muller C, et al: Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis- dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 56: 141-146, 1999. (Pubitemid 29309822)
34. Kuo CC, Liu JF and Chang JY: DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther 316: 946-954, 2006.
35. Takahashi T, Min Z, Uchida I, et al: Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett 220: 85-93, 2005. (Pubitemid 40312021)